Prophylaxis RCT for ivermectin and iota-carrageenan in Argentina with 234 healthcare workers showing significantly lower cases with treatment. No paper is available yet but results are reported on clinicaltrials.gov.
Chahla et al., 1/11/2021, Randomized Controlled Trial, Argentina, South America, preprint, 1 author, dosage 12mg weekly.
risk of COVID-19 case, 94.7% lower, RR 0.05, p = 0.003, treatment 0 of 117 (0.0%), control 9 of 117 (7.7%), moderate/severe COVID-19.
risk of COVID-19 case, 84.0% lower, RR 0.16, p < 0.001, treatment 4 of 117 (3.4%), control 25 of 117 (21.4%), all cases.
Effect extraction follows pre-specified rules prioritizing more serious
outcomes. For an individual study the most serious outcome may have a smaller
number of events and lower statistical signficance, however this provides the
strongest evidence for the most serious outcomes when combining the results of